After the addition of PwC to the mix a couple weeks earlier, CPI revealed a contract today with Pfizer, making it the most recent partner of the Medicines Production Development Centre partnership. The collaboration will enable the Centre to bring into play Pfizer’s pharma understanding to assist attend to crucial difficulties and optimize performance within the medications supply chain.
Pfizer will work together with CPI, the University of Strathclyde, PwC and establishing market partners GSK and AstraZeneca. The Centre’s objective is to advance emergent and disruptive innovations through different flagship “Grand Obstacle” tasks to increase efficiency and client results in the pharma market.
The brand-new collaboration with Pfizer will focus on Grand Obstacle 1, which wants to produce an ingenious constant direct compression (CDC) platform that makes it possible for oral strong dose medications to be developed more effectively. The CDC platform will consist of a digital twin and information predictor design to permit the modeling of procedures in a digital area. This ability is anticipated to enhance effectiveness and reduce the amount of beginning products required to improve solutions, with the goal of motivating business to establish solutions quicker and at a lowered expense.
Pfizer will be supplying information, professional ability and understanding of constant mixing innovation.